- Home
- GSIW vs CALC Comparison
GSIW vs CALC Comparison
Compare GSIW & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- CALC
- Stock Information
- Founded
- GSIW 2016
- CALC 2011
- Country
- GSIW Hong Kong
- CALC United States
- Employees
- GSIW N/A
- CALC N/A
- Industry
- GSIW
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- CALC Health Care
- Exchange
- GSIW Nasdaq
- CALC Nasdaq
- Market Cap
- GSIW 27.2M
- CALC 22.9M
- IPO Year
- GSIW 2023
- CALC N/A
- Fundamental
- Price
- GSIW $1.60
- CALC $1.61
- Analyst Decision
- GSIW
- CALC Strong Buy
- Analyst Count
- GSIW 0
- CALC 3
- Target Price
- GSIW N/A
- CALC $16.33
- AVG Volume (30 Days)
- GSIW 2.2M
- CALC 28.5K
- Earning Date
- GSIW 01-01-0001
- CALC 08-11-2025
- Dividend Yield
- GSIW N/A
- CALC N/A
- EPS Growth
- GSIW N/A
- CALC N/A
- EPS
- GSIW N/A
- CALC N/A
- Revenue
- GSIW $1,313,795.00
- CALC N/A
- Revenue This Year
- GSIW N/A
- CALC N/A
- Revenue Next Year
- GSIW N/A
- CALC N/A
- P/E Ratio
- GSIW N/A
- CALC N/A
- Revenue Growth
- GSIW N/A
- CALC N/A
- 52 Week Low
- GSIW $0.35
- CALC $1.42
- 52 Week High
- GSIW $12.30
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- GSIW 74.17
- CALC 49.89
- Support Level
- GSIW $1.48
- CALC $1.59
- Resistance Level
- GSIW $1.64
- CALC $1.69
- Average True Range (ATR)
- GSIW 0.13
- CALC 0.15
- MACD
- GSIW -0.02
- CALC 0.01
- Stochastic Oscillator
- GSIW 80.00
- CALC 52.26
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.